Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases
- Yutaka Tsutsumi
- Shinichi Ito
- Jun Nagai
- Takahiro Tateno
- Takanori Teshima
Affiliations: Department of Hematology, Hakodate Municipal Hospital, Hakodate, Hokkaido 041‑8680, Japan, Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060‑8638, Japan
- Published online on: August 9, 2021 https://doi.org/10.3892/mco.2021.2371
Copyright: © Tsutsumi
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Primary dural low‑grade marginal zone B‑cell lymphoma of mucosa‑associated lymphoid tissue (MALT) is a rare disease whose main treatment has been local surgery or radiotherapy. Until now, there have been no cases of dural MALT lymphoma treatment of a patient with several relapses or systemic disease. The present study included two patients with dural MALT lymphoma who had several relapses or systemic disease. Since local therapy was not enough to control the disease for these patients, they were treated with systemic chemotherapy. The patients were administered rituximab (375 mg/m2) and two days of bendamustine (90 mg/m2). Both patients recovered from their clinical symptoms immediately, and their tumors were reduced. During and after rituximab and bendamustine therapy, no central nervous system (CNS) metastasis or cerebrospinal fluid invasion of MALT were observed. The current approach using rituximab and bendamustine treatment was effective against dural MALT lymphoma and may prevent its invasion of the CNS.